Erratum to: Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan
| Autor: | K, Moriwaki, M, Mouri, H, Hagino |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Cost-Benefit Analysis
Endocrinology Diabetes and Metabolism Sensitivity and Specificity Zoledronic Acid Drug Administration Schedule Drug Costs Japan Fracture prevention Humans health care economics and organizations Osteoporosis Postmenopausal Aged Alendronate Bone Density Conservation Agents Diphosphonates Hip Fractures Cost-effectiveness analysis Imidazoles Health Care Costs Injections Intravenous Osteoporosis Spinal Fractures Original Article Female Quality-Adjusted Life Years Erratum Health economics Models Econometric Osteoporotic Fractures |
| Zdroj: | Osteoporosis International |
| ISSN: | 1433-2965 0937-941X |
| Popis: | Summary Model-based economic evaluation was performed to assess the cost-effectiveness of zoledronic acid. Although zoledronic acid was dominated by alendronate, the incremental quality-adjusted life year (QALY) was quite small in extent. Considering the advantage of once-yearly injection of zoledronic acid in persistence, zoledronic acid might be a cost-effective treatment option compared to once-weekly oral alendronate. Introduction The purpose of this study was to estimate the cost-effectiveness of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan. Methods A patient-level state-transition model was developed to predict the outcome of patients with osteoporosis who have experienced a previous vertebral fracture. The efficacy of zoledronic acid was derived from a published network meta-analysis. Lifetime cost and QALYs were estimated for patients who had received zoledronic acid, alendronate, or basic treatment alone. The incremental cost-effectiveness ratio (ICER) of zoledronic acid was estimated. Results For patients 70 years of age, zoledronic acid was dominated by alendronate with incremental QALY of −0.004 to −0.000 and incremental cost of 430 USD to 493 USD. Deterministic sensitivity analysis indicated that the relative risk of hip fracture and drug cost strongly affected the cost-effectiveness of zoledronic acid compared to alendronate. Scenario analysis considering treatment persistence showed that the ICER of zoledronic acid compared to alendronate was estimated to be 47,435 USD, 27,018 USD, and 10,749 USD per QALY gained for patients with a T-score of −2.0, −2.5, or −3.0, respectively. Conclusion Although zoledronic acid is dominated by alendronate, the incremental QALY is quite small in extent. Considering the advantage of annual zoledronic acid treatment in compliance and persistence, zoledronic acid may be a cost-effective treatment option compared to alendronate. Electronic supplementary material The online version of this article (doi:10.1007/s00198-017-3973-8) contains supplementary material, which is available to authorized users. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink